Ipamorelin vs CJC-1295: Evidence, DAC, and Safety

Compare Ipamorelin and CJC-1295 mechanisms, DAC and no-DAC naming, human GH evidence, combination gaps, safety, FDA status, and sourcing checks.

Ipamorelin and CJC-1295 are experimental growth-hormone secretagogues with different targets and very different human evidence. They are frequently sold together, but “both raise growth hormone” is not enough to establish that a blend is effective, safe, or even chemically identified correctly.

The most important distinction is often missed: the human CJC-1295 pharmacology studies evaluated a long-acting, albumin-binding compound associated with the DAC modification. A product marketed as “CJC-1295 without DAC” is a different active moiety and should not inherit the long half-life or human results of CJC-1295 DAC.

Short answer

Ipamorelin is a five-amino-acid growth-hormone secretagogue receptor agonist. In healthy male volunteers receiving intravenous infusions, its terminal half-life was about two hours and it produced a brief growth-hormone pulse.
CJC-1295 DAC is a modified 29-amino-acid growth-hormone-releasing hormone analog designed to bind serum albumin. Small studies in healthy adults reported a roughly 5.8–8.1-day half-life and sustained increases in growth hormone and IGF-1.
CJC-1295 without DAC is not interchangeable with CJC-1295 DAC. FDA treats the DAC and non-DAC forms as different active moieties.
There is no human head-to-head trial showing that Ipamorelin is better than CJC-1295, and no controlled human outcomes trial establishing that their combination is synergistic.
Neither compound has established human evidence for fat loss, muscle gain, anti-aging, sleep improvement, or athletic recovery.
Neither is an FDA-approved drug. FDA has raised characterization, safety, and compounding concerns for both.
The evidence does not support a dosing schedule, cycle, or self-administration protocol.

Comparison at a glance

Question	Ipamorelin	CJC-1295 DAC	“CJC-1295 without DAC”
Primary target	Growth-hormone secretagogue/ghrelin receptor	Pituitary GHRH receptor	Intended to act at the GHRH receptor, but exact identity must be established
Defined structure	Pentapeptide containing non-proteinogenic amino acids	29-amino-acid GHRH analog plus an albumin-binding MPA-Lys unit	Marketplace name is ambiguous; often used for a non-DAC GHRH analog
Best human pharmacology	IV dose-escalation study in healthy men	Small SC studies in healthy adults	FDA did not identify human studies establishing activity for the non-DAC free base or acetate
Reported human half-life	About 2 hours after IV infusion	About 5.8–8.1 days after SC administration	Do not transfer the DAC half-life; the page label alone cannot establish it
Human clinical outcome evidence	Failed to significantly improve the primary endpoint in a postoperative-ileus trial	Hormone and short-term safety studies, not body-composition or longevity trials	No established clinical outcome evidence located
FDA status	Not approved; FDA proposed against 503A Bulks List inclusion	Not approved; FDA proposed against inclusion of all five evaluated CJC-1295 forms	Same regulatory and identity concerns apply

Mechanism: two routes into the GH axis

Ipamorelin and CJC-1295 act at different receptors upstream of growth hormone.

Ipamorelin is a synthetic pentapeptide—H-Aib-His-D-2-Nal-D-Phe-Lys-NH2—that activates the growth-hormone secretagogue receptor. This is the receptor family activated by ghrelin. Early pharmacology characterized Ipamorelin as relatively selective for growth-hormone release compared with older growth-hormone-releasing peptides, but much of that selectivity work was conducted in animals. “Selective” does not mean clinically proven or free of effects elsewhere.

CJC-1295 is a 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It acts through the GHRH receptor on pituitary somatotrophs. The DAC form adds an MPA-bound lysine that reacts with serum albumin, greatly extending exposure. That chemical modification is central to the compound's observed pharmacokinetics; it is not a minor packaging option.

Both mechanisms depend on a functioning pituitary GH axis. A rise in a hormone concentration is a pharmacodynamic result, not proof of improved body composition, recovery, sleep, or long-term health.

What does “CJC-1295 with DAC” mean?

FDA's 2024 review separated five CJC-1295-related bulk drug substances:

CJC-1295 free base
CJC-1295 acetate
CJC-1295 DAC free base
CJC-1295 DAC acetate
CJC-1295 DAC trifluoroacetate

FDA further identified two different active moieties: non-DAC CJC-1295 and CJC-1295 DAC. They are not interchangeable. Free-base and salt forms are also distinct bulk drug substances with different chemical properties.

Online sellers often use “CJC-1295 no DAC” and “Mod GRF 1-29” as if they were universal synonyms. A marketing name does not establish the sequence, terminal groups, counterion, purity, or pharmacokinetics. FDA documented inconsistent naming even in nomination packages and public chemical records.

For that reason, a comparison should not say “CJC-1295 has an eight-day half-life” without identifying the DAC form. The long-acting result belongs to the albumin-binding compound evaluated in the human studies.

Human evidence for Ipamorelin

Growth-hormone pharmacology

A dose-escalation study infused Ipamorelin over 15 minutes in healthy male volunteers. The investigators reported dose-proportional pharmacokinetics, a terminal half-life of about two hours, and a single growth-hormone release episode that peaked at about 0.67 hours before declining to negligible concentrations.

This establishes short-term IV pharmacology in healthy men. It does not establish a subcutaneous half-life, a chronic-use profile, or a health benefit.

Postoperative ileus trial

The most substantial published clinical outcome study randomized adults after bowel resection to intravenous Ipamorelin or placebo. Among 114 people in the safety and modified intention-to-treat populations, median time to tolerating a standardized solid meal was 25.3 hours with Ipamorelin and 32.6 hours with placebo; the difference was not statistically significant (p=0.15). FDA concluded that the primary and secondary efficacy analyses did not support effectiveness for postoperative ileus.

Two deaths occurred among Ipamorelin-treated surgical patients with serious postoperative complications. FDA stated that it was unclear whether the deaths were related to Ipamorelin. That uncertainty should be preserved: the trial does not prove the compound caused the deaths, but it also does not establish broad safety for other populations or routes.

What the Ipamorelin evidence does not show

Rat studies have reported bone growth, bone dimensions, and other physiological effects. These do not establish human improvements in bone density, fat loss, muscle gain, pain, sleep, or fertility. FDA found no evidence supporting the proposed subcutaneous use for growth-hormone deficiency or postoperative ileus and no safety data for the proposed subcutaneous route.

Human evidence for CJC-1295 DAC

Two small randomized, double-blind, placebo-controlled dose-escalation studies evaluated CJC-1295 in healthy adults. The studied compound behaved as the albumin-binding DAC form. After one subcutaneous injection, mean growth hormone increased for six days or more and mean IGF-1 increased for roughly 9–11 days. The estimated half-life was 5.8–8.1 days. After repeated doses, mean IGF-1 remained above baseline for up to 28 days.

A related study sampled healthy men overnight one week after administration. It reported higher trough and mean growth-hormone secretion and higher IGF-1 while pulse frequency and magnitude were preserved.

These studies establish hormone changes in small groups of healthy adults over short periods. They did not establish treatment of growth-hormone deficiency, durable fat loss, increased muscle strength, faster recovery, improved sleep, or longer life. FDA also noted uncertainty about the exact salt used in the published studies and found no human effectiveness data for the non-DAC free base or acetate forms.

Is the Ipamorelin and CJC-1295 combination synergistic?

The mechanistic argument is straightforward: one compound stimulates the ghrelin/GHS receptor and the other stimulates the GHRH receptor, so the pair might produce a different growth-hormone response than either alone.

That is a hypothesis, not a demonstrated patient benefit. The reviewed literature did not identify a randomized human trial comparing Ipamorelin alone, CJC-1295 alone, and the combination. It also did not identify a controlled human study showing that the blend improves body composition, sleep, recovery, or another clinical outcome.

Combining two experimental compounds also combines uncertainty. It can make attribution of adverse effects difficult and creates additional identity, ratio, compatibility, and stability questions. The existence of separate single-compound pharmacology studies does not validate a premixed vial.

Which is better for fat loss, muscle, sleep, or anti-aging?

There is no defensible winner because the required human outcome evidence is missing.

Intended outcome	What is established	What remains unproven
Fat loss	Both can alter GH-axis biomarkers under studied conditions	Clinically meaningful fat loss from either compound or their combination
Muscle gain	GH and IGF-1 are involved in tissue physiology	Increased strength, function, or durable lean mass in controlled trials
Sleep	GH secretion has a sleep-related rhythm	Treatment of insomnia or improvement in validated sleep outcomes
Recovery	No direct comparative clinical trial located	Faster exercise, injury, or surgical recovery
Anti-aging	No accepted clinical anti-aging endpoint was studied	Longer lifespan, healthspan, or reversal of aging

Comparisons to tesamorelin, recombinant growth hormone, or weight-management drugs cannot be used to estimate Ipamorelin or CJC-1295 outcomes. Similar pathway labels do not make products clinically interchangeable.

Safety and regulatory status

Neither Ipamorelin nor any evaluated CJC-1295 form is a component of an FDA-approved drug, and FDA reported no applicable USP or National Formulary drug-substance monograph for them.

FDA's 2024 compounding reviews proposed not adding Ipamorelin free base, Ipamorelin acetate, or any of the five evaluated CJC-1295 forms to the section 503A Bulks List. FDA cited inconsistent identity information, incomplete characterization, limited effectiveness evidence, and safety uncertainties. Its current safety-risk page notes potential immunogenicity from peptide aggregation or impurities for both substances.

For CJC-1295, FDA identified increased heart rate, injection-site reactions, and systemic vasodilatory reactions such as flushing, warmth, and transient hypotension in the limited human data. For Ipamorelin, FDA noted events in the postoperative-ileus trial and the absence of safety data for the proposed subcutaneous route. GH-axis stimulation can also raise concerns such as glucose intolerance, fluid retention, and effects on underlying disease, but risks cannot be quantified for unapproved formulations from the available studies.

Advisory-committee recommendations are not drug approvals, and regulatory status can change. This section was reviewed on August 29, 2026; use FDA's current compounding pages for later decisions.

Research sourcing and identity checks

The first purchasing question is not “which peptide is stronger?” It is “what compound and form does the record actually identify?” For legitimate analytical or laboratory work, check:

Exact name and sequence: Ipamorelin, non-DAC CJC-1295, and CJC-1295 DAC must be distinguishable from the label alone.
Modification: For CJC-1295, confirm whether the albumin-binding MPA-Lys unit is present. Do not infer it from a half-life claim.
Salt and counterion: Free base, acetate, and trifluoroacetate are distinct forms; counterion content affects mass and characterization.
Identity versus purity: Mass spectrometry can support identity, while a chromatographic purity percentage addresses a different question. Both should map to the same lot.
Per-component blend data: A blend needs identity and assay data for each component, the measured ratio, compatibility and stability evidence, and lot-linked raw records.
Peptide-specific impurities: Review deletion sequences, incomplete coupling products, residual solvents and reagents, aggregates, water, and counterion content.
Route-sensitive controls: A route-sensitive laboratory protocol may require sterility, bacterial endotoxin, particulate, aggregation, and container-closure evidence; HPLC purity alone cannot answer these questions.

The source directory helps compare public identity and batch-record documentation. Listings are informational, not endorsements for human use, and “research use only” material is not demonstrated safe for self-administration.

References

FDA. Evaluation of CJC-1295-related bulk drug substances. Pharmacy Compounding Advisory Committee; 2024.
FDA. Evaluation of Ipamorelin-related bulk drug substances. Pharmacy Compounding Advisory Committee; 2024.
FDA. Certain bulk drug substances for compounding that may present significant safety risks. Reviewed August 29, 2026.
Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.
Ionescu M, Frohman LA. Pulsatile GH secretion persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006.
Gobburu JVS, et al. Pharmacokinetic-pharmacodynamic modeling of Ipamorelin in human volunteers. Pharm Res. 1999.
Beck DE, et al. Randomized proof-of-concept study of Ipamorelin for postoperative ileus. Int J Colorectal Dis. 2014.
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
Svensson J, et al. Ipamorelin and GHRP-6 increase bone mineral content in adult female rats. J Endocrinol. 2000.
FDA. October 29, 2024 Pharmacy Compounding Advisory Committee meeting.

Bottom line

Ipamorelin produces a relatively short GH pulse in human IV pharmacology, while the albumin-binding CJC-1295 DAC form produces prolonged GH and IGF-1 elevation. Those hormone patterns do not establish superiority, combination synergy, or benefits for fat loss, muscle, sleep, recovery, or aging. The safest evidence-based comparison begins by identifying the exact CJC-1295 form, separating biomarkers from outcomes, and refusing to transfer DAC data to an ambiguously labeled non-DAC product.

Ipamorelin vs CJC-1295: Evidence, DAC, and Safety

On this page